Summary of Trisalus Life Sciences FY Conference Call Company Overview - Company: Trisalus Life Sciences (NasdaqGM: TLSI) - Industry: Oncology-focused medical technology - Market Opportunity: $2.5 billion market in liver embolization procedures, currently growing at over 50% per year [2][24] Core Technology and Innovations - Technology: Catheter-based system that enhances drug delivery to tumors while minimizing exposure to normal tissue - Patent Portfolio: Over 100 patents, with 20-25 patents filed annually, focusing on pressure modulation for optimal tumor perfusion [3][2] - Drug Delivery Efficiency: Achieves 50%-500% more drug delivery to tumors compared to traditional methods [7][8] Clinical and Economic Impact - Patient Outcomes: Improved overall survival rates and reduced complications due to targeted drug delivery [8][10] - Cost Savings: CMS saves approximately $8,000 per procedure due to reduced hospital readmissions [10][11] - Reimbursement: Favorable reimbursement landscape with a proprietary embolization code, enhancing hospital revenue [13][10] Product Portfolio and Market Penetration - Current Devices: Two devices launched in 2020 and 2021, with plans to introduce two additional sizes to cater to various vascular anatomies [11][12] - Market Share: Currently holds a 9% share in the liver embolization market, with significant growth potential [14] - Expansion into Other Applications: Technology is being adapted for uterine fibroids, thyroid nodules, and pancreatic treatments, among others [15][19][20] Future Growth Opportunities - New Applications: Exploring embolization procedures for osteoarthritis and other orthopedic conditions, which could significantly change treatment paradigms [22][23] - Collaborations: Partnerships with other drug companies to enhance drug delivery systems and improve treatment outcomes [20][21] - Market Strategy: Targeting 400 hospitals and 1,000 doctors, focusing on a concentrated market approach [13][14] Financial Outlook - Growth Guidance: Current year growth projected at 50%, with future guidance under review [28] - Cost Management: Focus on reducing R&D and G&A expenses while maintaining positive Adjusted EBITDA by mid-year [29][30] - Revenue Performance: Achieved approximately $12 million in revenue last quarter, with gross margins around 85% [30][31] Additional Insights - Unique Selling Proposition: The technology's ability to modulate pressure and flow allows for better treatment outcomes and minimizes complications [6][7] - Regulatory Strategy: Plans to gather clinical data to support inclusion in treatment guidelines, which could drive adoption [26][27] This summary encapsulates the key points discussed during the Trisalus Life Sciences FY Conference Call, highlighting the company's innovative technology, market opportunities, and financial outlook.
Trisalus Life Sciences (NasdaqGM:TLSI) FY Conference Transcript